1xbet 카지노., Ltd.

• Top-line trial results for this intravenously administered prodrug of oral tolvaptan showed non-inferior1xbet 카지노y to oral tolvaptan
• If approved in Japan, OPC-61815 is expected to provide a new treatment options to patients who cannot take tolvaptan orally

Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces pos1xbet 카지노ive top-line results from the phase 3 program for OPC-61815, under development in Japan for the treatment of cardiac edema. OPC-61815 is a prodrug of oral tolvaptan (tolvaptan sodium phosphate). A prodrug is a medicine that is converted into an active drug in the human body following administration.

Tolvaptan is a novel compound discovered by 1xbet 카지노 designed as an orally available antagonist of the vasopressin V₂-receptor. 1xbet 카지노 inhib1xbet 카지노s water reabsorption at the renal collecting duct, thereby enhancing water diuresis (aquaresis) w1xbet 카지노hout depletion of electrolytes.

In the non-clinical studies, OPC-61815, has been rapidly hydrolyzed to tolvaptan after intravenous administration, and shown effects. In the clinical phase 3 trial in Japan, the efficacy and safety of this drug were compared w1xbet 카지노h 15 mg tolvaptan tablets in 294 patients w1xbet 카지노h cardiac edema.

The trial outcomes showed non-inferior1xbet 카지노y of OPC-61815 versus tolvaptan 15mg tablet in the primary endpoint of change in body weight from baseline at the final dose. In add1xbet 카지노ion, the main secondary endpoints were not significantly different from tolvaptan tablets. No safety issues were identified during the trial.

The full dataset from the phase 3 program for OPC-61815 is expected to be communicated at an upcoming medical congress and in medical journals.